Avidity Biosciences Dec 2022 – Meet the DM Drug Developers

Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy sit down with our community to share their progress and answer your questions.

The Avidity Biosciences team presents, « MARINA Data: A Preliminary Assessment from the Phase 1/2 Clinical Trial for DM1 » on December 16, 2022. Click here to read their recent press release and open letter to the DM Community.

Click here to learn more about Avidity Biosciences.

Presenters include:

• Kelly DiTrapani, RN, BSN, BA
  Avidity Biosciences, Vice President of Medical Affairs
• Nicholas Johnson, MD, MSCI, FAAN
  Virginia Commonwealth University, MARINA Principal Investigator
• Mike Flanagan, PhD
  Avidity Biosciences, Chief Technical Officer

Click here to find all our recorded Meet the DM Drug Developer sessions.